Galactorrhea affects 24% women, not linked to breast cancer

Ghaziabad, Jan 23 (IANS) Galactorrhea, in which a whitish or greenish discharge occurs from the nipples, affects nearly 24 per cent of women but has no association with breast cancer, health experts said on Thursday.

Galactorrhea is a milky nipple discharge unrelated to the normal milk production for breastfeeding. It is not a disease itself but could be a sign of an underlying problem. It usually occurs in women, even those who have never had children or after menopause.

According to the doctors at Columbia Asia Hospital in Ghaziabad, pre-menopausal women who are not breastfeeding may experience a condition where they produce breast milk.

The condition may indicate high levels of the hormone prolactin in the body, caused mainly by some malfunction in the pituitary gland that produces the hormone, the experts said.

"Galactorrhea may occur when your body produces too much prolactin, (a hormone produced by the pituitary gland in the brain that stimulates the production of milk when a woman has a baby). Any woman who has had a baby, whether or not she breast-fed her baby, may later have galactorrhea," said Vinita Diwakar, Obstetrics and Gynaecology department, Columbia Asia Hospital.

"Too much estrogen in the body due to birth control pills or an underactive thyroid gland can also cause the condition. Nipple stimulation due to sexual activity or sports activities such as jogging, can also increase prolactin production," Diwakar added.

According to the hospital, some of the other causes of galactorrhea may include consumption of drugs, such as oral contraceptive pills, some high blood pressure medications, sedatives and antidepressants; disorders or non-cancerous tumours of the pituitary gland; opivid use violactinoma other medical conditions such as kidney failure, cirrhosis of the liver, and tumours of the spinal cord.

If the breast tissue is particularly sensitive to prolactin in blood, it may cause idiopathic galactorrhea - the reason for which remains unknown.

"In men, galactorrhea may cause testosterone deficiency or male hypogonadism and usually occurs with breast enlargement or tenderness (gynecomastia). It may also cause erectile dysfunction and a lack of sexual desire due to testosterone deficiency," Diwakar said.

If a woman experiences a mild idiopathic galactorrhea, a tight breast support may help stop the discharge by preventing stimulation of the nipples, the doctor said.

"In newborns, galactorrhea may be caused due to high maternal estrogen levels that cross the placenta and reaches the baby''s blood. This can enlarge the baby''s breast tissue, which may be associated with a milky nipple discharge, though it is temporary and resolves on its own. If the discharge is persistent, consult a doctor," Diwakar stressed.

--IANS

bu/rt/bg

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: IANS

Original post:
Galactorrhea affects 24% women, not linked to breast cancer - Outlook India

Recommendation and review posted by Bethany Smith

Cryonics Technology Market research report provides an actual industry viewpoint, future trends and dynamics for market growth rate, market size, trading and key players of the industry with forecast period of 2027. It provides a comprehensive analysis of various business aspects such as global market trends, recent technological advancements, market shares, size, and new innovations. According to researchers, demand for the global market will expand to a noticeable CAGR over the period from 2020 to 2027.

A thorough study of the competitive landscape of the Cryonics Technology Market has been given along with the insights of the companies, financial status, trending developments, mergers & acquisitions and SWOT analysis. This research will give a clear and precise idea about the overall market to the readers to take beneficial decisions.

Request Sample Copy of this Report @: https://www.itintelligencemarkets.com/request_sample.php?id=36078

Top Key Players: Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR

Key Questions Answered in Report:

What is major factor which lead this market to next level?

What will the market Demand and what will be Growth?

What are the latest opportunities to Endoscopy Trolley Market in future?

What are the strengths of the key players?

What are the key of Endoscopy Trolley Market?

The market in Asia Pacific is expected to witness the fastest growth in the Global Cryonics Technology Market over the forecast period. Recent and upcoming Global opportunities have been analyzed across several Global regions, such as North America, Latin America, Asia-Pacific, Europe, and India.

Get Reasonable Discount on this Premium Report @: https://www.itintelligencemarkets.com/ask_for_discount.php?id=36078

At last, it comprises the systematic explanation of the various factors such as the Cryonics Technology Market growth and a detailed information about the different companys revenue, growth, technological developments, production and the various other strategic developments.

Major Factors:

1. Global Cryonics Technology Market Overview

2. Economic Impact on Industry

3. Market Competition by Manufacturers

4. Production, Revenue (Value) by Region

5. Supply (Production), Consumption, Export, Import by Regions

6. Production, Revenue (Value), Price Trend by Type

7. Market Analysis by Application

8. Manufacturing Cost Analysis

9. Industrial Chain, Sourcing Strategy and Downstream Buyers

10. Marketing Strategy Analysis, Distributors/Traders

11. Market Effect Factors Analysis

12. Global Cryonics Technology Market Forecast

For More Information: https://www.itintelligencemarkets.com/enquiry_before_buying.php?id=36078

About Us:

At IT Intelligence Markets, we model all our work on our core philosophy that believes in customer satisfaction. We serve a global clientele by supplying market intelligence research reports after conducting exhaustive research. Our reports are replete with productive insights & recent market dynamics as the healthcare industry is constantly undergoing changes like ever-changing consumer preferences, supply channels and latest technologies. Our market research analysts not only investigate the market for drivers, restraints & challenges but also gauge the overall progress of the market by comparing chief market players. Our report forms a crucial piece of intelligence using which our clients can unleash their potential & tap their capacity to harness the correct technologies & surpass their competitors.

Contact us:

Erika Thomas

US 76 AT US 19 & HWY 129 Murphy Highway,

Blairsville, GA, USA

sales@itintelligencemarkets.com

Phone: +1 (888) 312-3102

https://www.itintelligencemarkets.com

Erika Thomas

View all posts byErika Thomas

View post:
Cryonics Technology Market Emerging Trends and Prospects 2027 With Leading Players Praxair - VOICE of Wisconsin Rapids

Recommendation and review posted by Bethany Smith

Sorry Mom and Dad: It turns out you might not have been exaggerating when you told us your children made your hair turn gray.

Stress may play a key role in just how quickly hair goes from colored to ashen, a study published this past week in the journal Nature suggests.

Scientists have long understood some link is possible between stress and gray hair, but this new research from Harvard University in Massachusetts more deeply probes the exact mechanisms at play.

The researchers initial tests looked closely at cortisol, the stress hormone that surges in the body when a person experiences a fight or flight response.

Its an important bodily function, but the long-term presence of heightened cortisol is linked to a host of negative health outcomes.

But the culprit ended up being a different part of the bodys fight or flight response the sympathetic nervous system.

These nerves are all over the body, including making inroads to each hair follicle, the researchers reported.

Chemicals released during the stress response specifically norepinephrine causes pigment producing stem cells to activate prematurely, depleting the hairs reserves of color.

The detrimental impact of stress that we discovered was beyond what I imagined, Ya-Chieh Hsu, PhD, a lead study author and an associate professor of stem cell and regenerative biology at Harvard, said in a press release. After just a few days, all of the pigment-regenerating stem cells were lost. Once theyre gone, you cant regenerate pigments anymore. The damage is permanent.

But stress isnt the only or even the primary reason that most people get gray hair.

In most cases, its simple genetics.

Gray hair is caused by loss of melanocytes (pigment cells) in the hair follicle. This happens as we age and, unfortunately, there is no treatment that can restore these cells and the pigment they produce, melanin, Dr. Lindsey A. Bordone, a dermatologist at ColumbiaDoctors and an assistant professor of dermatology at Columbia University Medical Center in New York, told Healthline. Genetic factors determine when you go gray. There is nothing that can be done medically to prevent this from happening when it is genetically predetermined to happen.

That doesnt mean environmental factors such as stress dont play a role.

Smoking, for instance, is a known risk factor for premature graying, according to a 2013 study. So kick the habit if you want to keep that color a little longer.

Other contributing factors to premature graying include deficiencies in protein, vitamin B-12, copper, and iron as well as aging due in part to an accumulation of oxidative stress.

That stress is prompted by an imbalance between free radicals and antioxidants in your body that can damage tissue, proteins, and DNA, Kasey Nichols, NMD, an Arizona physician and a health expert at Rave Reviews, told Healthline.

And some degree of oxidative stress is a natural part of life.

We would expect increasing gray hair as we advance in age, and we see about a 10 percent increase in the chance of developing gray hair for every decade after age 30, Nichols said.

Changes you can pursue to delay premature grays include eating a diet high in omega-3 fatty acids such as walnuts and fatty fish, not spending too much time in the skin-damaging and hair-damaging ultraviolet light of the sun, and taking vitamin B-12 and vitamin B-6 supplements.

That said, if you are going gray prematurely, it wouldnt hurt to go have a checkup just in case natural genetic factors arent the sole culprit.

The new Harvard research is only a mouse study, so replicating the same results in a human study would be necessary to strengthen the findings.

But the Harvard research has implications far beyond graying hair, with the hair color change merely one obvious sign of other internal changes as a result of prolonged stress.

By understanding precisely how stress affects stem cells that regenerate pigment, weve laid the groundwork for understanding how stress affects other tissues and organs in the body, said Hsu. Understanding how our tissues change under stress is the first critical step towards eventual treatment that can halt or revert the detrimental impact of stress.

Might that also mean someday halting and reverting the march of premature gray hair? Its too soon to tell.

We still have a lot to learn in this area, Hsu said.

See original here:
Scientists Think They Know How Stress Causes Gray Hair - Healthline

Recommendation and review posted by Bethany Smith

Scientists now say they may have discovered that stress makes your hair go grey.

Science really is just catching up on things we already knew.

I bet theres a team following bears around with a bucket and a map (spoiler alert, you might want to head to the woods).

The researchers from American and Brazil teamed up to do experiments on mice.

They found stem cells that control skin and hair colour became damaged after intense stress.

Firstly, did they realise that some mice are white already? I hope so.

Secondly, how much stress does a mouse go through?

I thought this would explain why, if you have faced redundancy or are moving house, you might start to notice the odd grey strand.

Do mice worry about job losses?

Does Mr Mouse go home and tell his wife that Bagpuss has announced cutbacks and they all have to reapply for their positions?

How can this research help humans?

If you want to keep your glowing, coloured hair avoid the stress of going near cats?

The stem cells that create hair colour are used up doing times of stress.

Does this mean the more hair cells you have the better you will be at dealing with stress?

That is more bad news for balding people like myself, although if you include back hair I might be the most resilient person alive.

As ever, I think this piece of science news can help me get to my first million.

Im going to make money selling grey hair dye.

Not hair dye for grey hair, dye to turn your hair grey.

Everyone loves to claim that theyre really busy and stressed these days. If you ask how someone has been they will tell you how much of a challenge theyre up against in a bid to get some sympathy from you.

With Steve N Allens new improved Greycian 2000 you can look like youre so stressed your stem cells ran out years ago.

Steve N Allen is a comedian and broadcaster who was raised in Sutton-in-Ashfield.

Here is the original post:
Take the stress out of going grey by just going grey before you start - Mansfield and Ashfield Chad

Recommendation and review posted by Bethany Smith

With so many groundbreaking medical advances being revealed to the world every single day, you would imagine there would be some advancement on the plethora of many female-prevalent diseases (think female cancers, Alzheimer's, depression, heart conditions etc.) that women are fighting every single day.

For Anna Villarreal and her team, there frankly wasn't enough being done. In turn, she developed a method that diagnoses these diseases earlier than traditional methods, using a pretty untraditional method in itself: through your menstrual blood.

Getting from point A to point B wasn't so easy though. Villarreal was battling a disease herself and through that experience. I wondered if there was a way to test menstrual blood for female specific diseases," she says. "Perhaps my situation could have been prevented or at least better managed. This led me to begin researching menstrual blood as a diagnostic source. For reasons the scientific and medical community do not fully understand, certain diseases impact women differently than men. The research shows that clinical trials have a disproportionate focus on male research subjects despite clear evidence that many diseases impact more women than men."

There's also no denying that gap in women's healthcare in clinical research involving female subjects - which is exactly what inspired Villarreal to launch her company, LifeStory Health. She says that, with my personal experience everything was brought full circle."

There is a challenge and a need in the medical community for more sex-specific research. I believe the omission of females as research subjects is putting women's health at risk and we need to fuel a conversation that will improve women's healthcare.,"

-Anna Villarreal

Her brand new biotech company is committed to changing the women's healthcare market through technology, innovation and vocalization and through extensive research and testing. She is working to develop the first ever, non-invasive, menstrual blood diagnostic and has partnered with a top Boston-area University on research and has won awards from The International Society for Pharmaceutical Engineering and Northeastern University's RISE.

How does it work exactly? Proteins are discovered in menstrual blood that can quickly and easily detect, manage and track diseases in women, resulting in diseases that can be earlier detected, treated and even prevented in the first place. The menstrual blood is easy to collect and since it's a relatively unexplored diagnostic it's honestly a really revolutionary concept, too.

So far, the reactions of this innovative research has been nothing but excitement. The reactions have been incredibly positive." she shares with SWAAY. Currently, menstrual blood is discarded as bio waste, but it could carry the potential for new breakthroughs in diagnosis. When I educate women on the lack of female subjects used in research and clinical trials, they are surprised and very excited at the prospect that LifeStory Health may provide a solution and the key to early detection."

To give a doctor's input, and a little bit more of an explanation as to why this really works, Dr. Pat Salber, MD, and Founder of The Doctor Weighs In comments: researchers have been studying stem cells derived from menstrual blood for more than a decade. Stem cells are cells that have the capability of differentiating into different types of tissues. There are two major types of stem cells, embryonic and adult. Adult stem cells have a more limited differentiation potential, but avoid the ethical issues that have surrounded research with embryonic stem cells. Stem cells from menstrual blood are adult stem cells."

These stem cells are so important when it comes to new findings. Stem cells serve as the backbone of research in the field of regenerative medicine the focus which is to grow tissues, such as skin, to repair burn and other types of serious skin wounds.

A certain type of stem cell, known as mesenchymal stem cells (MenSCs) derived from menstrual blood has been found to both grow well in the lab and have the capability to differentiate in various cell types, including skin. In addition to being used to grow tissues, their properties can be studied that will elucidate many different aspects of cell function," Dr. Salber explains.

To show the outpour of support for her efforts and this major girl power research, Villarreal remarks, women are volunteering their samples happily report the arrival of their periods by giving samples to our lab announcing de-identified sample number XXX arrived today!" It's a far cry from the stereotype of when it's that time of the month."

How are these collections being done? Although it might sound odd to collect menstrual blood, plastic cups have been developed to use in the collection process. This is similar to menstrual products, called menstrual cups, that have been on the market for many years," Dr. Salber says.

Equally shocking and innovative, this might be something that becomes more common practice in the future. And according to Dr. Salber, women may be able to not only use the menstrual blood for early detection, but be able to store the stem cells from it to help treat future diseases. Companies are working to commercialize the use of menstrual blood stem cells. One company, for example, is offering a patented service to store menstrual blood stem cells for use in tissue generation if the need arises."

See original here:
How I Went From Managing Complexity to Becoming a U.S. Ambassador and CEO - SWAAY

Recommendation and review posted by Bethany Smith

If you havent chanced upon a gua sha stone facial or a jade roller video on your social media, are you even on it? The ancient Chinese technique of face massaging is gaining traction thanks to beauty bloggers sharing their basic kneads. If you have stumbled upon these videos but have no clue whats going on, read on. Dermatologist Dr Nirupama Parwanda says that the basics come from traditional Chinese wisdom: improper blood circulation and stagnant blood flow is one of the main reasons behind various diseases. To improve circulation and drain toxins, you can try jade rollers and gua sha an alternative therapy that involves massaging your skin using special tools. Parwanda says, Our bodies have a source of energy known as chi flowing through it. And to ensure good health and prosperity, we must balance it. Dr Rinky Kapoor, dermatologist and dermato-surgeon, explains, Both rollers and gua sha are made of stones such as quartz, jade, rose quartz and amethyst known for their healing properties. Gua sha is also known as coining, skin scrapping or pressure stroking. FLOW AND GLOWBoth work on the principle of improving blood flow under the skin and enhancing lymphatic drainage. This helps carry the oxygen to the skin cells, which in turn makes the skin tissues healthy, and reduces fine lines and wrinkles. Parwanda says that gua sha is also called natural botox as it helps in controlling signs of ageing. The proven benefits are: pain reduction in muscles and joints; reduction in perimenopause symptoms like anxiety, insomnia, hot flashes; improved blood circulation, removal of toxins. It also treats musculoskeletal disorders and reduces wrinkles.

TOO GOOD TO BE TRUE?Kapoor cautions that just looking at videos online doesnt mean you know the proper way to use it. You need to follow the process to reap the maximum benefits. Also, theres not one simple process for both jade roller and gua sha. Think of it as driving while the basics of accelerator, brake and clutch remain the same, driving styles are different, she says. Start both facials from the neck and then move upwards and with upward strokes. Rollers are simpler to use as you can just start massaging on the outward and upward direction from one point, except for the neck, where the massaging motion is downwards. Gua sha facials require more technique. Tip: you can learn from a practitioner.

Continue reading here:
Roll play: Jade rollers and gua sha stone are making waves in skincare - Times of India

Recommendation and review posted by Bethany Smith

With so many groundbreaking medical advances being revealed to the world every single day, you would imagine there would be some advancement on the plethora of many female-prevalent diseases (think female cancers, Alzheimer's, depression, heart conditions etc.) that women are fighting every single day.

For Anna Villarreal and her team, there frankly wasn't enough being done. In turn, she developed a method that diagnoses these diseases earlier than traditional methods, using a pretty untraditional method in itself: through your menstrual blood.

Getting from point A to point B wasn't so easy though. Villarreal was battling a disease herself and through that experience. I wondered if there was a way to test menstrual blood for female specific diseases," she says. "Perhaps my situation could have been prevented or at least better managed. This led me to begin researching menstrual blood as a diagnostic source. For reasons the scientific and medical community do not fully understand, certain diseases impact women differently than men. The research shows that clinical trials have a disproportionate focus on male research subjects despite clear evidence that many diseases impact more women than men."

There's also no denying that gap in women's healthcare in clinical research involving female subjects - which is exactly what inspired Villarreal to launch her company, LifeStory Health. She says that, with my personal experience everything was brought full circle."

There is a challenge and a need in the medical community for more sex-specific research. I believe the omission of females as research subjects is putting women's health at risk and we need to fuel a conversation that will improve women's healthcare.,"

-Anna Villarreal

Her brand new biotech company is committed to changing the women's healthcare market through technology, innovation and vocalization and through extensive research and testing. She is working to develop the first ever, non-invasive, menstrual blood diagnostic and has partnered with a top Boston-area University on research and has won awards from The International Society for Pharmaceutical Engineering and Northeastern University's RISE.

How does it work exactly? Proteins are discovered in menstrual blood that can quickly and easily detect, manage and track diseases in women, resulting in diseases that can be earlier detected, treated and even prevented in the first place. The menstrual blood is easy to collect and since it's a relatively unexplored diagnostic it's honestly a really revolutionary concept, too.

So far, the reactions of this innovative research has been nothing but excitement. The reactions have been incredibly positive." she shares with SWAAY. Currently, menstrual blood is discarded as bio waste, but it could carry the potential for new breakthroughs in diagnosis. When I educate women on the lack of female subjects used in research and clinical trials, they are surprised and very excited at the prospect that LifeStory Health may provide a solution and the key to early detection."

To give a doctor's input, and a little bit more of an explanation as to why this really works, Dr. Pat Salber, MD, and Founder of The Doctor Weighs In comments: researchers have been studying stem cells derived from menstrual blood for more than a decade. Stem cells are cells that have the capability of differentiating into different types of tissues. There are two major types of stem cells, embryonic and adult. Adult stem cells have a more limited differentiation potential, but avoid the ethical issues that have surrounded research with embryonic stem cells. Stem cells from menstrual blood are adult stem cells."

These stem cells are so important when it comes to new findings. Stem cells serve as the backbone of research in the field of regenerative medicine the focus which is to grow tissues, such as skin, to repair burn and other types of serious skin wounds.

A certain type of stem cell, known as mesenchymal stem cells (MenSCs) derived from menstrual blood has been found to both grow well in the lab and have the capability to differentiate in various cell types, including skin. In addition to being used to grow tissues, their properties can be studied that will elucidate many different aspects of cell function," Dr. Salber explains.

To show the outpour of support for her efforts and this major girl power research, Villarreal remarks, women are volunteering their samples happily report the arrival of their periods by giving samples to our lab announcing de-identified sample number XXX arrived today!" It's a far cry from the stereotype of when it's that time of the month."

How are these collections being done? Although it might sound odd to collect menstrual blood, plastic cups have been developed to use in the collection process. This is similar to menstrual products, called menstrual cups, that have been on the market for many years," Dr. Salber says.

Equally shocking and innovative, this might be something that becomes more common practice in the future. And according to Dr. Salber, women may be able to not only use the menstrual blood for early detection, but be able to store the stem cells from it to help treat future diseases. Companies are working to commercialize the use of menstrual blood stem cells. One company, for example, is offering a patented service to store menstrual blood stem cells for use in tissue generation if the need arises."

View post:
What I Learned About Marriage as a Survivor of Abuse - SWAAY

Recommendation and review posted by Bethany Smith

Marie Antoinette's hair suddenly turned white before the ill-fated French queen was taken to the guillotine to have her head chopped off, according to some historical accounts.

More modern reports refer to hair turning prematurely white in survivors of bomb attacks during World War II, while an Australian airline pilot saw his hair go grey in the months after landing a plane following a failure of all four engines in the early 1980s.

While there's been plenty of anecdotal evidence suggesting premature greying can be caused by extreme stress -- whether this is true and how this happens isn't widely understood.

Now, Harvard University scientists think they have the answer -- at least in mice.

The group of researchers believe it's down to the animal's sympathetic nervous system -- which is best known for activating our "fight or flight" response to danger, they say.

"Under stress, our sympathetic nerve becomes highly activated," said Ya-Chieh Hsu, associate professor of stem cell and regenerative biology at Harvard, in an email. "And actually, activation of the sympathetic nervous system under stress is supposed to be a good thing."

Its activation triggers the "fight or flight" response through the neurotransmitter norepinephrine, or noradrenaline, explained Hsu, a senior author of the study published Wednesday in the scientific journal Nature. "Noradrenaline raises our heartbeat and allows us to react quickly to danger without having to think about it," he said.

"However, it is the same noradrenaline that turns out to be bad for melanocyte stem cells at a high level, and triggers their loss."

Melanocyte stem cells are found in hair follicles and determine hair colour. In people, the pool of these cells deplete as they age, turning hair grey as pigment depletes. Their loss from excessive noradrenaline could be causing this to happen prematurely, the team suggest.

Loss of pigment

The team had thought that acute stress might trigger an immune attack on pigment-producing stem cells or that the blame lied with the hormone cortisol because cortisol levels are elevated under stress. Hsu said they went through many different possibilities before focusing on the sympathetic nervous system.

"We were really surprised to find that it was the culprit, because it is normally seen as a beneficial system, or at least transient and reversible," she said.

The team put mice under three different types of stress through what Hsu described as established standard protocols. These included a single injection of a chemical to activate the mouse's pain fiber, cage tilting and rapid changes between light and dark.

Changes were observed in all mice but there was some variability, with white hair only coming out after all the stem cells are gone.

"Some hair follicles have reduced levels of melanocyte stem cells so they can still make pigment, while others have lost all stem cells and can't make pigment anymore, so the hair becomes white," she said.

Pigment-producing stem cells and the sympathetic nervous system are very similar in mice and humans, explained Hsu who was hopeful that the mechanisms would be related. But future studies would be needed to provide definitive evidence, she said.

"Everyone has an anecdote to share about how stress affects their body, particularly in their skin and hair the only tissues we can see from the outside," Hsu said in a news release.

"We wanted to understand if this connection is true, and if so, how stress leads to changes in diverse tissues. Hair pigmentation is such an accessible and tractable system to start with and besides, we were genuinely curious to see if stress indeed leads to hair greying."

Hsu said the findings may also help shed light on the effects of stress on various organs and tissues, and pave the way for new studies that seek to modify or block the damaging effects of stress.

In an accompanying article, Shayla Clark and Christopher Deppmann, researchers from the Neuroscience Graduate Program at the University of Virginia, who were not involved in the study, said it was interesting to consider what possible evolutionary advantage might be conferred by stress-induced greying.

"Because grey hair is most often linked to age, it could be associated with experience, leadership and trust. Perhaps an animal that has endured enough stress to 'earn' grey hair has a higher place in the social order than would ordinarily be conferred by that individual's age," they wrote.

Continued here:
Scientists prove link between stress and prematurely greying hair - Newstalk ZB

Recommendation and review posted by Bethany Smith

Everyone sheds about 100 hairs each day as part of the normal hair growth cycle, but excess loss is usually a distressing development.(iStock)

Hair loss is typically considered the domain of aging men, but this equal-opportunity condition which has many causes can affect virtually anyone.

Alopecia is the medical term for hair loss, and it doesnt only happen on the scalp. Some illnesses and medications can trigger balding over the entire body, though genetics account for most cases on the head, according to theCleveland Clinic.

PARTY DRUG MDMA A STEP CLOSER TO LEGALIZATION FOR PTSD THERAPY

Everyone sheds about 100 hairs each day as part of the normal hair growth cycle, but excess loss is usually a distressing development. Americans spend more than $3.5 billion each year trying to treat it, according to theAmerican Hair Loss Association.

Most peoples hair grows about a half-inch per month, and about 90 percentof your hair is actively growing at any given time, with the other 10 percentin dormant phase. After two or three months, this dormant hair falls out and its follicles begin growing new hair as other follicles begin a dormant phase.

Shedding hair is different from hair loss, when a hair falls out and doesnt grow back. People often shed hair during stressful events, such aschildbirth, a breakup or divorce or during times of grief.

It still doesnt feel good, and it takes the hair [awhile] to reach a certain length where you perceive its presence, said Doris Day, a board-certified dermatologist New York City and an attending physician at Lenox Hill Hospital, also in New York. So it feels like a hair loss, but its not a hair loss.

Aside from heredity, noticeable hair loss can be caused by wide variety of factors, including:

Harsh hairstyles or treatments: Hairstyles that consistently use rubber bands, rollers or barrettes, or pull hair into tight styles such as cornrows, can inflame and scar hair follicles. So can incorrectly used chemical products such as dyes, bleaches, straighteners or permanent wave solutions. Depending on the degree of damage, resulting hair loss can be permanent.

Hormone imbalances: In women, hormonal shifts from birth control pills,pregnancy, childbirth, menopause or hysterectomy can induce more hair follicles than normal to enter the dormant phase.

Illness or surgery: The stress from sickness or surgery may prompt the body to temporarily cease nonessential tasks such as hair production. Specific conditions can also trigger it, including thyroid disorders,syphilis, iron deficiency,lupusor severe infection. An autoimmune condition called alopecia areata, which has no cure, causes rapid body-wide hair loss.

Medications and vitamins: Cancer chemotherapy, which attacks hair follicles in its attempt to kill all fast-growing cells around the body, is a well-known reason for hair loss. Other medications side effects include hair shedding as well, such as some that treat high blood pressure andgout(a painful joint condition caused by a buildup of uric acid). Excessive levels of vitamin A also contribute.

Nutritional deficits: Heavy dieting or eating disorders such asbulimiaandanorexiacan temporarily stun hair follicles to cease growth. This can also occur from insufficient protein, vitamin or mineral intake.

Aging: A natural effect of growing older is slowed hair growth.

Women usually dont go completely bald, but lose hair on the top of the head or the temples. Men tend to lose hair on their temples, and are more likely than women to go completely bald, Day said.

Dermatologists will examine the persons scalp and take a history of medical or stressful events to see whats been going on in their life and their world, Day said.

HELICOPTER-SHARING APP BLADE PAIRS WITH NYU LANGONE TO SPEED TRANSPLANT ORGANS

The dermatologist may take a biopsy a small patch of skin that includes the hair follicle and send it to a pathologist to determine if an autoimmune disease, such as lupus, is the cause of the hair loss.

Examining the hair and follicle can also determine whether someone has a bacterial or fungal infection, Day said.

Hair loss remedies range from the mild to the extreme and the inexpensive to the costly. Much depends on how much hair is gone and how high a priority it is to mask its absence or replace it.

According to the Cleveland Clinic, treatments include:

Hair weaves or wigs: Typically expensive, wigs and hair weaves either completely cover the head or add to existing hair, restoring the appearance of a full head of hair. They are especially practical for cancer patients and those whose hair loss is temporary.

Topical creams and lotions: Over-the-counter minoxidil (also known as the brand name Rogaine) can restore some hair growth, especially in those with hereditary hair loss. It is applied directly to the scalp. Prescription-strength finasteride (Propecia) comes in pill form and is only for men. According to theAmerican Academy of Family Physicians(AFP), it may take up to six months to tell if these medications are working.

Anti-inflammatory medications: Prescription steroid-based creams or injections can calm follicles damaged or inflamed by harsh chemicals or excessive pulling.

Surgery: Men tend to be better candidates for surgical hair-replacement techniques because their hair loss is often limited to one or two areas of the scalp. Procedures include grafting, which transplants from one to 15 hairs per disc-shaped graft to other locations. Scalp reduction removes bald skin from the scalp so hair-covered scalp can be stretched to fill in the bald areas. Side effects include swelling, bruising and headaches.

Hair-growth laser treatment can also help stimulate hair follicles and improve growth, Day said. People often see results when they combine laser treatment with another intervention, she said. Treatments range in price from $30 and up for Rogaine to about $3,000 for laser treatment, she added.

According to theNational Institute of Arthritis and Musculoskeletal and Skin Diseases(NIAMSD), alternative therapies may not help hair regrow and many are not supported by medical research. However, other treatments that reportedly improve alopecia areata include Chinese herbs, acupuncture, zinc and vitamin supplements, evening primrose oil and aroma therapy.

Viviscal, a natural supplement, has also shownmore hair growthin men compared to those who took fish extract in clinical trials, Day said.

The NIAMSD recommends discussing any alternative treatments with physicians before use.

The drug Tofacitinib is approved to treat adults witharthritis, but a growing number of cases suggest that it can also treat alopecia universalis, a condition in which people lose all of the hair on their body because theirimmune systemattacks hair follicles,Live Science previously reported.

The finding occurred after doctors prescribed a 25-year-old man with alopecia universalis the drug because they had heard it had treated a similar condition in mice,according to a statement from Yale University. After three months of treatment, the man had completely regrown the hair on his scalp, and he had visible eyebrows, eyelashes, facial hair, as well as hair elsewhere on his body.

Its exciting, said Day, who did not treat this particular patient. There seems to be a real effect here.

CLICK HERE TO GET THE FOX NEWS APP

Its unclear how Tofacitinib (brand name Xeljanz) works, but researchers hope to determine its mechanism soon. This data may help them learn which biological pathways lead to hair loss.

There are now clinical trials taking place around the country to test the safety and efficacy of the drug for hair loss conditions. One such study lasting 3 months gave Tofacitinib to 66 people with alopecia areata (an immune system condition that causes hair to fall out in patches). Half of the people regrew some hair, and one-third had more than 50 percentof the hair on their scalp grow back, according to the 2016 study, published in the journalJCI Insight.

However, researchers are still working to determine the best dose needed, whether the results are lasting, and whether they can develop a topical form of the drug, Day said. She added that patients should be aware that Tofacitinib has side effects. Its already associated with an increased risk of serious infections, as well as stomach and intestinal tears, according to Pfizer, the manufacturer.

Besides investigating Tofacitinib, researchers are also looking at ways to clone hair or use stem cell therapy to treat alopecia, Day said.

This article first appeared on LiveScience.

Visit link:
Alopecia: What causes the hair loss condition? - foxwilmington.com

Recommendation and review posted by Bethany Smith

Former President Barack Obama is pictured at the beginning of his presidency in January 2009 and at the end, during President Donald Trumps inauguration eight years later. Harvard researchers, for the first time, have discovered how stress turns hair gray. AP file photos

Back in 2009, a New York Times article appeared with the headline, After 44 days in the White House, Obamas hair is grayer. The article referred to a common trend of presidents hair turning dramatically gray during their terms in the Whitehouse.

This idea of stress turning hair gray has pervaded popular culture for centuries. Its often referred to as Marie Antoinette syndrome, in reference to an oft-told, but most likely apocryphal, story of the ill-fated French queens hair turning white overnight after being captured during the revolution.

While the idea of ones hair turning white in an instant after a sudden fright is an amusing cartoonish fiction, there is a solid body of anecdotal evidence describing instances where hair rapidly turns white after months, or even weeks, of stress or trauma.

In a new mouse study published in the journal Nature, scientists from Harvard linked the sympathetic nervous systemthe one thats behind your fight or flight responseto developing gray hair. When youre stressed out, your system releases the neurotransmitter norepinephrine, which primes your body for action.

The researchers discovered that norepinephrine damages melanocyte stem cells, which help regenerate color within your hair follicles. As a result, if youre often stressed, you can prematurely develop gray hair.

During the study, researchers put mice through three different types of stress. All mice had some changes in their hair color, but only the ones who lost all of their melanocyte stem cells after intense stress developed white hair. Stress isnt the only factor: Previous research has also suggested that melanocyte stem cells are simply damaged with time.

When we started to study this, I expected that stress was bad for the body but the detrimental impact of stress that we discovered was beyond what I imagined, study author Ya-Chieh Hsu, Ph.D., said in a statement. After just a few days, all of the pigment-regenerating stem cells were lost. Once theyre gone, you cant regenerate pigments anymore. The damage is permanent.

Of course, this study was conducted on mice, not humans, but the idea works in theory for people, too, says Gary Goldenberg, M.D., an assistant clinical professor of dermatology at the Icahn School of Medicine at Mount Sinai in New York City.

Popular belief has always been that physical and emotional stress causes ones hair to turn gray. Weve known for a while that melanocytes in the hair follicles are a lot more sensitive than the same cells that reside in the skin, Dr. Goldenberg says. Therefore stress, whether oxidative, hormonal, or inflammatory, can cause destruction of these cells.

Finding ways to de-stress can do wonders for your whole bodynot just your hair. We know that stress has a negative impact on our health and skin in general, says Joshua Zeichner, M.D., director of cosmetic and clinical research in dermatology at Mount Sinai Hospital in New York City.

He says that stress has been shown to impair wound healing, promote acne breakouts, and worsen skin conditions like eczema and psoriasis. (Not to mention, it can also boost your risk of life-threatening conditions, like heart disease.)

Of course, stressing less could help improve your healthand possibly even slow down your graysbut thats simply easier said than done. Its not enough to say dont stress, since this is something most of us cant control, Dr. Goldenberg says. But helping your body diminish normal stress may be helpful.

He recommends doing your best to eat a nutrient-rich diet, hydrate often, and exercise regularly to be kind to your body and lower your natural stress levels. (Check out these science-backed ways to relax, too.)

And, if you develop gray hair anyway, embrace itits a natural part of getting older.

(with inputs from Agencies)

See the article here:
Study finds that stress really can turn your hair gray - Khabarhub

Recommendation and review posted by Bethany Smith

Healthcare, a constantly evolving and growing space is ascending to the next level with Additive Manufacturing (AM) or 3D printing, which is a process of creating three dimensional solid objects by means of a digital file. 3D printing is being effectively used across many industries and is now finding increasing usage in the medicine and pharmaceutical sector as well. Here are some of the revolutionary advancements of 3D printing.

As 3D printing has revolutionized the manufacturing process, doctors and researchers are hopeful that it will benefit millions of people in need of artificial braces and limbs. 3D printing is one of the most sought after innovations that introduced less expensive prosthetics. Individuals pay anywhere between three lakh rupees to thirty lakhs rupees for prosthetics. With 3D printing, the cost drops considerably to an astonishing 3000 rupees, resulting in economic viability.

In a recent testing, researchers have exhibited a model for a 3D bioprinter that can make operational human skin. It can be used on patients who require skin grafting, for clinical studies and research experiments as well as the testing of pharmaceutical, chemical, and cosmetic, products. It is also apt for use in transplants on burn patients and those with other skin problems.

The need for partial skull replacements has increased in the recent past. In dangerous accidents where the skull of an individual is damaged beyond repair, skull plates are fixed to allow continuous functionality. The skull is first scanned to create a digital replica, before a replacement plate s printed out. This step in 3D printing is a boon for crucial and Immediate skull replacement surgeries.

Doctors have recently honed an innovative method to develop a fully formed human ear, utilizing the patients own stem cells. By beginning with a 3D printed polymer mould of an ear, the procedure involves implanting stem cells that are derived from fat.

Personalised dosage is another revolutionary step in 3D printing that will benefit millions, globally. A doctor would be able to use each patients individual information to customise and produce an optimal medication dose, rather than relying on a standard set of dosages.

Although, 3D printing in the pharmaceutical sector witnessed greater advancements, there is much to explore and develop further. Nevertheless, there is a constant process of upgrading and enhancing current printing technology and materials.

Follow this link:
How 3D Printing Is Changing Healthcare - Version Weekly

Recommendation and review posted by Bethany Smith

New Delhi, Jan 24 : Breast cancer in men is rarely seen. It shares many similarities with cancer of the breast in women but there are some important differences too.

Male breast cancer represents between 0.5 and 1 per cent of all breast cancers diagnosed each year. Higher rates of male breast cancer in central and eastern Africa may be related to higher liver infectious diseases that lead to hypoestrogenism.

Dr Kumardeep Dutta Choudhury, Senior Consultant & Head of Department, Dept of Medical Oncology (IOSPL), Fortis Hospital, Noida, shares the facts you need to know about it.

Risk factors associated with breast cancer in men:Genetics and family historyFamily history of breast cancer in a first-degree relative is associated with an increased risk of breast cancer among men. Approximately 15 to 20 per cent of men with breast cancer have a family history of the disease compared with only 7 per cent of the general male population.

The risk is higher with inherited BRCA2 rather than BRCA1 mutations. Other genes which have been associated with an increased risk of breast cancer in men are PTEN tumor suppressor gene (Cowden syndrome), tumor protein p53 (TP53; Li-Fraumeni syndrome), partner and localizer of BRCA2 (PALB2), and mismatch repair genes (Lynch syndrome).

Alterations of the estrogen to androgen ratioExcessive estrogen stimulation may be due to hormonal therapies (e.g., estrogen-containing compounds or testosterone), hepatic dysfunction, obesity, marijuana use, thyroid disease, or an inherited condition, such as Klinefelter syndrome may increase risk of male breast cancer.

Primary testicular conditionsTesticular conditions may increase risk of breast cancer in men include orchitis, undescended testes (cryptorchidism), and testicular injury.

PRESENTATION:Male breast cancer has been diagnosed at a more advanced stage than female breast cancer, due to a lack of awareness. They generally present with a painless, firm mass that is usually subareolar, with nipple involvement in 40 to 50 percent of cases. The left breast is involved slightly more often than the right, and less than 1 percent of cases are bilateral. There may be associated skin changes, including nipple retraction, ulceration, or fixation of the mass to the skin or underlying tissues. Axillary nodes are typically palpable in advanced cases.

Most histologic subtypes of breast cancer seen in women are also present in men, men with breast cancer are rarely diagnosed with lobular carcinomas is due to lack of acini and lobules in the normal male breast, although these can be induced in the context of estrogenic stimulation.

TREATMENT:Approach to treatment in men is same as that for women. However, role of breast conserving surgery is limited because of small volume of breast tissue. In hormone receptor-positive disease, we give adjuvant tamoxifen rather than an aromatase inhibitor (AI), because of insufficient evidence to support AI monotherapy for men. If there are contraindications to tamoxifen (e.g., hypercoagulable state), an AI with GnRHa may be administered. AIs do not reduce testicular production of estrogens, that's why GnRHa is administered concurrently with AI. They are treated with mastectomy, radiotherapy, chemotherapy and hormone therapy.

SURVEILLANCE:Limited data suggest these patients are at an increased risk of a contralateral breast cancer, but absolute risk is low. They are also at risk for secondary malignancies and 12.5 percent may develop a second primary cancer. The most common types were gastrointestinal, pancreas, non-melanoma skin, and prostate cancerPROGNOSIS:Ten-year disease-specific survival rates for histologically negative nodes - 77 and 84 per cent, one to three positive nodes - 50 and 44 per cent and four or more histologically positive nodes - 24 and 14 per cent.

-- The story has been published from a wire feed without any modifications to the text

See more here:
All you need to know about Male Breast Cancer - Prokerala

Recommendation and review posted by Bethany Smith

RECENTLY Ive been searching for a word that describes our present system of government.Liberal democracyisnt quite right (though it has features of both) because the phrase omits too many of its other features: notably, the rise and dominance of cranks, the casual overriding of well-established professional rules, and the imposition of formal and informal censorship on matters of controversy.

All three hang together, and all are dealt with below, but the key one seems to me to be the rise and dominance of cranks. Several people have suggested that the wordidiocracyis the one for which Ive been looking. Its also the title of a clever comedy of a few years back which some commentators predictably argue forecast the presidency of Donald Trump. Its producers have recently coined the witty advert: The film that started as a comedy . . . but became a documentary. Fair play to them. Its a funny movie, now on video. Watch it.

But its not about Trump who, though an infuriating mix of cleverness, boldness, impulsiveness, touchiness and at times mean-spiritedness, is not an idiot, still less a crank. Theyre not the same thing, anyway. An idiot is simply a stupid person. A crank may actually be quite clever, but hes in possession of One Big Idea (or maybe two) that drives him to promote it interminably and with no sense of proportion or practicality.

Cranks have been around in politics a long time, probably always Swift lampoons them as projectors inGullivers Travels but there seem to be more of them around since the rise of ideological politics in the French Revolution and, still more significantly, with the later rise of socialism. Ideological politics are the attempt to use government to implement some ambitious project of human betterment that will avert a vast catastrophe and bring about a new ideal society without greed, inequality, division and other human vices. Both the end of the world and utopia usually figure in ideology, and its sometimes hard to tell them apart.

Crankery figures too. The nineteenth century socialist theoretician Saint-Simon believed that under socialism the oceans would turn into lemonade. That didnt happen because it was fanciful nonsense and, besides, there werent any socialist governments around to give it a try. Stalin was around in Russia by the 1930s, however, and as part of the campaign to improve grain production, he supported applying the cranky anti-scientific theories of the geneticist Trofim Lysenko to agriculture (largely because they fitted in with Marxist ideology). Grain production and Soviet agriculture suffered, but Lysenkos theories remained Soviet orthodoxy until after Stalins death. Scientists who criticised them were dismissed in large numbers and some very distinguished geneticists were imprisoned and executed.

Theres an almost logical progression here. A government claims intellectual authority in some non-political field, genetics, say, or music. Some of its pronouncements run counter to established scientific truths, but they are backed by strong pressuresfrom loss of employment to execution, and the usual professional rules and legal safeguards designed to prevent the spread of quackeries are ignored from a prudent cowardice. And when the crankish policy begins to fail, censorship is imposed and its critics are dismissed, silenced, or worse.

Crankocracy = the rise of bogus experts + the junking of professional standards and legal protections x the repression of objectors.

We might think that with Saint-Simon and Lysenko in our history we would be alert in future to such dangers. Not so.

Marxist socialism is itself one vast exercise in crankery applied to politics, philosophy and economics, and it seems to have a family affection for lesser fallacies. But only thirty years since the collapse of Soviet communism revealed the economic wastelands and the mass graves of its political victims across the USSR, there is now a growing revival of support for socialism/communism/Marxism on the Left and among young people in the Western world.

And any large movement of perverse decadence, which this surely is, will be unlikely to leave other aspects of life alone. When the rules and protections and protections that sustain civilization in one area of life and thought begin to collapse, they knock down others elsewhere just as falling dominoes spread instability across an entire table. As Auden writes inThe Fall of Rome:

Fantastic grow the evening gowns;Agents of the Fisc pursueAbsconding tax defaulters throughThe sewers of provincial towns.

One might argue that in modernity, as in modernism and dominoes, everything is ultimately disconnected from everything else. Let me suggest two areas where crankery has already won significant victories. The first is genderand transgender theory. This holds that someones identity is not determined by his/her biological sex but by his/her gender identity, which may be malleable and is anyway a matter of individual conviction. As one slogan has it: If your boy says shes a girl, then shes a girl.

That seems false to me, but even if it were true, its effects should be limited at least by its own founding theory. Our social interactions with others, whatever their theoretical identities, should always be shaped by courtesy and goodwill, including treating them as they wish within reason. But we would surely not base a transwomans medical treatment on the assumption that her gender identity is a better guide than his biological sex to what they need.

Yet hospitals, schools, colleges and woke corporations do exactly that when they make available tampons to transwomen. Athletic bodies do likewise when they decree that transwomen with male bodies are eligible to play in womens sports, with the predictable result that many able women players who might win in a fair contest are defeated. If this goes uncorrected, it will simply end in the abolition of womens sports.

Admitting transwomen into womens-only safe spaces will similarly end a civilised protection for women in a world that certainly doesnt seem to be becoming less dangerous for them. Above all, as John Whitehall has documented inQuadrant,needless human tragedies and massive lawsuits are hurtling towards us when young people persuaded to undergo transitioning surgery and drug treatments that are life-changing and unalterable at an age when they cannot possibly understand the consequences believe in adulthood they have made a terrible mistake.

In all these cases the major institutions of society have capitulated to aggressive pressure groups pushing a theory that is highly dubious, unsupported by the great majority of clinical researches, regarded by many gays and feminists as a threat to their identities, and above all damaging to its supposed beneficiaries. Not enough attention has been devoted to examining the science behind the activism. A research project on gender-transitioning by the US National Institutes of Health (NIH) did not include the control group required by the rules. And as Madeleine Kearns ofNational Reviewhas detailed,when sceptics seek to raise these questions in public meetings, they are shouted down and threatened. Crankery or should it be quackery? is followed by ignoring the rules and enforced by repression.

Its a similar story in the academys history wars, reliant as they are on student rebellions (which in reality are highly conformist) and enforced by riots and iconoclasm. These, too, are a consequence of abolishing the border between truth and falsehood in postmodern scholarship. Of course, truth is sometimes hard to discover and to distinguish from persuasively false interpretations. The answer to that is more work in the archives. For postmodern historical interpretation was refuted in the 1920s by Georges Clemenceau, who led France in the Great War. A young historian kindly explained to him that future historians would re-examine the war from different perspectives and reach different conclusions different from his own. Yes, replied Clemenceau, future historians will say many things I might dispute. But one thing they will not say. They will not say that Belgium invaded Germany.

He may have been too optimistic. Relieved of the obligations of truth and accuracy, students all too often replace research with the pre-cooked conclusions of Marxist Critical Theory, as illustrated by theNew York Times1619 Project,which starts from the conclusion that slavery is the true essence of American history. As historian Richard Brookhiser said when asked about this recently: Two weeks before those first slaves landed, the colony adopted a democratic constitution. No one owns slaves in America today. But were still voting. How often will such rebuttals be heard in colleges in which the administrators as well as the students are striving to decolonise the curriculum, and when in effect both co-operate to close down debates and shut out speakers who might enlighten them. Once again, academic (and media) crankery is followed by, first, throwing overboard the rules of scholarship and, next, by the banishment of heretics.

It might reasonably be objected that not all of these are examples of rule by cranks. In part, thats a fair criticism. The cranks are in the streets; the corridors of power contain the cowards who yield to them. But Im not sure thats much of a comfort. Im getting the queasy feeling that in about five years anyone who has criticised Greta Thunbergs absurd views on the demise of Planet Earth by next Thursday will be up before the magistrates. It seems agreed by all well-meaning people that its a coarse and brutal insensitivity to express any scepticism aboutArmageddon predicted by a child.

All of which is a little odd, not least because the feisty Ms Thunberg is not a child. Shes a young woman of some 17 years, able to vote in progressive jurisdictions, and a rather typical self-righteous adolescent too. Now, it used to be a breach of feminist etiquette to refer to young women as if they were just starting high school. Yet we have not had any feminist complaints that Gretas honorary girlhood is an offensive slight even in these much woker days.

But could you have a better illustration of the coming crankocracy than the assembled leaders of the world nodding solemnly and applauding timidly as a 17-year-old adolescent condemns them angrily for not halting the medieval plague about to descend on them unless they replace their business suits with sackcloth and ashes?

They know their place.

This article first appeared in Quadrant Online on January 19, 2020, and is republished by kind permission.

- Advertisement -

Read more:
Greta and the rise of the crankocracy - The Conservative Woman

Recommendation and review posted by Bethany Smith

In October 2011, Amber Broman remembers sitting in the doctors office bawling, screaming and crying out.

Minutes earlier, she had learned that the baby girl she was carrying would likely never have the chance to talk or walk, ride a bike or drive a car or be walked down the aisle on her wedding day.

We had an amniocentesis and had noticed some abnormalities in the ultrasound, Broman noted. So we saw a specialist in Indianapolis and did an amnio there too. On the ultrasound, they initially saw multiple defects within her heart, and they didnt think her esophagus was attached to her stomach. And thats when they told me what it was and that it was in every cell of her body.

The condition was Trisomy 18.

It was five weeks before the Kokomo woman was to deliver, and all she remembers hearing that day were the words incompatible with life.

According to the National Institutes of Health, Trisomy 18 is a chromosomal genetic disorder that includes a combination of birth defects that impact nearly every organ in the body. People born with the disorder, also known as Edwards syndrome, have three copies of the 18th chromosome, and most babies with Trisomy 18 die within the first year of life.

She only lived two days, Broman said, referring to her daughter she named Khloe Nicole. We chose comfort care for her because we did not necessarily want to go through having her on machines and then making those decisions. We chose to just let life take its course, and we had almost 48 full hours with her.

Broman is not alone.

The CDC describes a birth defect as a structural change present at birth that can affect any or all parts of the body. They vary from mild to severe and depending on the type of defect, some infants can go on to live healthy lives.

In the United States, a baby is born with a birth defect every four-and-a-half minutes, according to the Indiana Birth Defects and Problems Registry, which equals roughly 120,000 babies per year.

In the Hoosier state, birth defects are the second leading cause of death for infants, with over 2,500 Indiana babies born each year with some type of congenital abnormality, such as a cardiovascular, chromosomal, central nervous system or musculoskeletal defect.

In 2018 alone, the Indiana State Department of Health concluded that birth defects contributed to 6.8 deaths per 1,000 births, a slight dip from 2017.

The infant mortality rate in Indiana is the lowest its been in six years, the ISDH noted, but the rate is still one of the highest in the nation.

In recent months, Gov. Eric Holcomb has taken the infant mortality plight to the public stage, making it one of the top priorities in his administration to have the lowest infant mortality rate in the Midwest by 2024.

The state has already begun the process of achieving that goal, rolling out programs and committees with the sole focus of lowering the infant mortality rate.

One of those programs, OB Navigator, was signed into law in 2019 and works in collaboration with the ISDH, the Indiana Family and Social Services Administration and the Indiana Department of Child Services.

OB Navigator was established by Indiana House Enrolled Act 1007 and is set in place to build a network of services and support throughout Indiana to wrap our arms around moms and babies to create healthier outcomes for both, its website states.

The program works as a connection tool between women who are early in their pregnancies and individuals who can provide personal guidance for those women through the rest of those pregnancies and at least the first six months of life.

Some of that guidance includes a Moms Helpline, which is a contact center that connects pregnant women throughout Indiana to available resources and a network of prenatal and child healthcare services, the programs website cites.

In a recent press release on the subject, State Health Commissioner Kristina Box noted that OB Navigator will be available to women on Medicaid in the states highest-risk counties, and organizers of the program anticipate enacting it in 20 counties by the end of 2020.

Visit the ISDHs website at in.gov/isdh/ for more information about the program.

While doctors do say that many birth defects cant necessarily be fully prevented, there are ways to lower the risk factor.

We usually dont start doing testing until about the second trimester of pregnancy, said Dr. Andrew Barlow, OBGYN at Trinity Health Network. We start offering blood tests and ultrasounds at that time to determine birth defects. However, there are women that can undergo screening beforehand if theyre at higher risks.

Women that fall into those categories are those over 35 or women with certain medical conditions, Barlow noted.

Because fetal growth, like organ development, takes place in the first few weeks of pregnancy, Barlow said its imperative to see your doctor on a regular basis if youre planning on becoming pregnant.

Review your medical history and make sure youre healthy enough to have children too, Barlow added. And make sure that youre not taking any medication that can contribute to birth defects. Also obviously dont abuse alcohol or drugs during pregnancy either.

Its also important to take a prenatal vitamin with the right amount of folic acid [400 mg], Barlow added, which having a deficiency of can lead to brain and spine defects like spina bifida or anencephaly. Spina bifida is a birth defect in which a developing babys spinal cord fails to develop properly. Anencephaly is the absence of a major portion of the brain, skull, and scalp that occurs during the development of the embryo.

Dr. Sheila Hockman, OBGYN at Ascension Medical Group and part of a state-wide Maternal Mortality Review Committee enacted to address the issue, agreed with Barlow, while also stressing that, such as in cases like young Khloes, there is really nothing that mothers can do to prevent such a defect.

However, areas like genetic testing can still be a giant help, even if a defect is already in place, she noted.

You can do genetic testing early in the pregnancy, Hockman said. And a lot of people, when we ask them if they want to do genetic testing, theyll say no because theyre going to deliver the baby regardless.

But for us, its not a matter of keeping the pregnancy or terminating it, she continued. Its the more well-prepared we are during the pregnancy, it enables us to care possibly in a different fashion. Do they need to see a maternal fetal medical specialist or can this pregnancy be monitored like a regular uncomplicated pregnancy? Its that sort of thing.

That can sometimes mean the difference between life and death, Hockman added.

The big point I would like to get across is that there are so many of these birth defects that are preventable, especially when you look at things like maternal obesity, she said. Its a national issue, but we can do something about it, and it often just takes a healthier lifestyle.

Go here to see the original:
'Incompatible with life': Birth defects second leading cause of death for infants in Indiana - Kokomo Tribune

Recommendation and review posted by Bethany Smith

A Senate committee is considering a bill that would make shelter animals and those rescued from shelters the official Florida state pet. That would put adopted cats and dogs alongside the manatee as the official state marine mammal, the alligator as the state reptile, the Florida panther as the state animal and the zebra longwing as the state butterfly.

TALLAHASSEE Sometimes Florida lawmakers fight like cats and dogs. Now they are fighting for cats and dogs.

Lawmakers are entering the third week of their annual 60-day session, and the Senate is taking up an abortion bill that's been divisive. But legislators are also taking up a number of measures that probably won't get "no" votes and likely won't get lawmakers in a lather of opposition.

Among them are animal bills. A Senate committee is considering a bill that would make shelter animals and those rescued from shelters the official Florida state pet. That would put adopted cats and dogs alongside the manatee as the official state marine mammal, the alligator as the state reptile, the Florida panther as the state animal and the zebra longwing as the state butterfly.

Another bill being considered would ban the declawing of cats unless it is medically necessary. The legislative staff analysis of the bill says people usually declaw cats to protect furniture and describes why cats should be able to hang on to their claws.

"A cat's claws play an important role in various aspects of their lives. They use their claws to assist in climbing and maintaining balance, to help them fully stretch, to relieve stress through kneading, and to escape danger," the analysis reads.

Another animal bill being considered would ban the practice of pet leasing. That's essentially when a pet dealer gives a customer a loan to pay for their pet, but then repossesses the pet when the loan can't be repaid.

Another measure that's not expected to generate vocal opposition: A proposed Senate resolution would reject and condemn white supremacy and any other philosophy that espouses one group over another on the basis of race, gender, religion, color or national origin.

The resolution won't become law, but rather send a strong message that the Senate doesn't like hate.

"These philosophies are contradictory to the values, constitutional protections, and moral fiber of the United States of America and the State of Florida," the resolution reads.

A bill that would force girls under the age of 18 to get a parent's permission before getting an abortion will be considered by the full Senate on Wednesday. It's an issue that's divided Democrats who say it's an erosion of abortion rights and Republicans who say parents should be part of the decision if their daughters have a medical procedure that could affect them the rest of their lives.

Senators will be able to ask questions about the bill and Democrats will have a ton of them but won't vote on the measure until the following week. The House is also prepared to vote on a similar bill, but will likely wait to receive the Senate version.

Republican Gov. Ron DeSantis supports the measure.

The full House will take up a bill that would bar insurance companies from using home genetic testing kits in making underwriting decisions. The legislation is sponsored by Rep. Chris Sprowls, who is next in line to become House speaker. He calls the measure a matter of privacy.

The bill seeks to outlaw life, disability and long-term care insurers from denying policies or setting premiums based on markers that might be discovered through DNA home kits.

Visit link:
Florida Legislature going to the dogs (and cats) - Destin Log

Recommendation and review posted by Bethany Smith

Chronic disease management startup Lark Health rolled out its "Lark Prevention" tool aimed at providing behavioral health coaching to patients at risk for developing chronic conditions,according to MobiHealth News.

Business Insider Intelligence

The AI-enabled program was designed to guide users through behavioral coaching to address health issues including weight management, smoking cessation, and stress users can select an initial health area to address, and once that program is completed, they can select a second area to focus on.

The rollout of the tool is the latest move Lark has taken to expand its scope of services and the launch could expand the size of its addressable market in the digital chronic disease management space.

Lark Health has been bolstering its diabetes and hypertension management services across the last year.The startup focused its early work in the chronic disease management space, aiming to personalize diabetes prevention and management.

Lark expanded on its personalized prevention tools through a January 2019partnershipwith genetic testing giant 23andMe to incorporate genetic test data into Lark's diabetes prevention software enabling Lark's health coaches to give users more personalized health care recommendations. And Lark is seeing impressive results with its chronic disease management endeavors: Larkannouncedin September 2019 that its hypertension management program was able to significantly reduce blood pressure and decrease the risk of stroke for patients following a period of six months.

With a growing number of US citizens at-risk for chronic conditions, the new launch could help Lark widen its addressable market as it branches into new treatment areas.For example, the new tool targets weight management, and obesity is a major health issue in the US: The prevalence of obesity was nearly 40% and affected about 93.3 million US adults in 2015-2016 alone,perthe CDC.

Further, obesity is often associated with chronic conditions like type 2 diabetes, stroke, heart disease, and certain cancers which represent some of the leading causes of preventable, premature death in the US.

The launch of Lark Prevention tool makes the startup an attractive option to payers thanks, in part, to its value-based care (VBC) billing approach.Payers who areincorporatingdigital tools into their benefits packages would likely view future partnerships with Lark Health as an enticing proposition: A whopping90%of US healthcare spending is funneled into managing and treating chronic conditions, and payers are looking for ways to curtail their share of spending on members with chronic disease.

And with Lark Prevention tool targeted to at-risk patients, payers could see the tool as a means to bypass the development or progression of costly chronic conditions, thus reducing spending in the long-term. Further, payers may have little to lose in a tie-up with Lark Health, considering it employs aVBC-basedbilling approach known as "no-risk performance-based billing" in which the startup only charges payers when its members enroll in Lark and achieve improved health outcomes, making it an even more attractive potential partner.

Want to read more stories like this one? Here's how to get access:

Original post:
Lark Health launched its preventative health tool for patients at risk of chronic conditions - Business Insider Nordic

Recommendation and review posted by Bethany Smith

Ghaziabad: Galactorrhea, in which a whitish or greenish discharge occurs from the nipples, affects nearly 24 percent of women but has no association with breast cancer, health experts said on Thursday.

Galactorrhea is a milky nipple discharge unrelated to the normal milk production for breastfeeding. It is not a disease itself but could be a sign of an underlying problem. It usually occurs in women, even those who have never had children or after menopause.

According to the doctors at Columbia Asia Hospital in Ghaziabad, pre-menopausal women who are not breastfeeding may experience a condition where they produce breast milk.

The condition may indicate high levels of the hormone prolactin in the body, caused mainly by some malfunction in the pituitary gland that produces the hormone, the experts said.

Galactorrhea may occur when your body produces too much prolactin, (a hormone produced by the pituitary gland in the brain that stimulates the production of milk when a woman has a baby). Any woman who has had a baby, whether or not she breast-fed her baby, may later have galactorrhea, said Vinita Diwakar, Obstetrics, and Gynaecology department, Columbia Asia Hospital.

Too much estrogen in the body due to birth control pills or an underactive thyroid gland can also cause the condition. Nipple stimulation due to sexual activity or sports activities such as jogging can also increase prolactin production, Diwakar added.

According to the hospital, some of the other causes of galactorrhea may include consumption of drugs, such as oral contraceptive pills, some high blood pressure medications, sedatives, and antidepressants; disorders or non-cancerous tumours of the pituitary gland; opivid use violactinoma other medical conditions such as kidney failure, cirrhosis of the liver, and tumours of the spinal cord.

If the breast tissue is particularly sensitive to prolactin in the blood, it may cause idiopathic galactorrhea the reason for which remains unknown.

In men, galactorrhea may cause testosterone deficiency or male hypogonadism and usually occurs with breast enlargement or tenderness (gynecomastia). It may also cause erectile dysfunction and a lack of sexual desire due to testosterone deficiency, Diwakar said.

If a woman experiences a mild idiopathic galactorrhea, a tight breast support may help stop the discharge by preventing stimulation of the nipples, the doctor said.

In newborns, galactorrhea may be caused due to high maternal estrogen levels that cross the placenta and reaches the babys blood. This can enlarge the babys breast tissue, which may be associated with a milky nipple discharge, though it is temporary and resolves on its own. If the discharge is persistent, consult a doctor, Diwakar stressed.

Read more here:
Galactorrhea affects 24% women, not linked to breast cancer - The Siasat Daily

Recommendation and review posted by Bethany Smith

BOSTON--(BUSINESS WIRE)--Akouos, a precision genetic medicine company developing gene therapies to potentially improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 43rd Annual Midwinter Meeting of the Association for Research in Otolaryngology (ARO), being held January 25 to January 29, 2020 in San Jose, CA.

Akouos continues to advance our platform for inner ear disorders, and we are excited to share our progress with the scientific community, said Greg Robinson, Ph.D., chief scientific officer of Akouos. The data presented at ARO further substantiates Akouoss use of AAVAnc80 vector technology and its potential to address many forms of hearing loss.

SYMPOSIUM

Title: The Adeno-associated Viral Anc80 (AAVAnc80) Vector - Precision Genetic Medicines to Address Hearing LossPresenter: Michelle Valero, Ph.D., Director, Anatomy & Physiology, AkouosSession: Symposium 11Date and Time: Saturday, January 25, 3 p.m. (PST)

POSTER PRESENTATIONS

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Olive Baboons (Papio anubis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Cynomolgus Macaques (Macaca fascicularis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: Dual Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Non-human PrimatesDay and Time: Monday, January 27, 1 p.m. (PST)

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to improve and preserve hearing. Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. For more information, please visit http://www.akouos.com.

About AAVAnc Technology

Ancestral AAV (AAVAnc) technology was developed in the laboratory of Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Harvard Medical School. AAVAnc technology uses computational and evolutionary methods to predict novel conformations of the adeno-associated viral particle. AAVAnc80, one of 40,000 AAVAnc vectors, has demonstrated preliminary safety and effective gene delivery in both mice and non-human primates in numerous preclinical studies.

See the original post:
Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meeting - Business Wire

Recommendation and review posted by Bethany Smith

New York, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Therapies Industry" - https://www.reportlinker.com/p05817674/?utm_source=GNW Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities. - Against the backdrop of tumor diversity, the universal "one size fits all" therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side-effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancers diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism. For instance, scientists are close to identifying the key molecule involved in cancers mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called "alternative splicing. Aberrations in alternative splicing are linked to cancers progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancers biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide. - Competitors identified in this market include, among others, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company , F. Hoffmann-La Roche Ltd., Glaxosmithkline Plc, Johnson & Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc.,Takeda Pharmaceutical Company Limited.

Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

CANCER THERAPIES MCP-1MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Cancer Therapies: An Outlook Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market By Cancer Type USA Leads the Cancer Therapies Market Biotherapies to Drive Growth Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth Total Number of New Cancer Cases by Type: 2018 Total Number of Cancer Deaths by Type: 2018 Cancer Incidence by Region: 2018 Cancer Mortality by Region: 2018 Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018 Cancer Research Spending Continues to Witness Growth Number of FDA-Approved Cancer Drugs: 2010-2018 Select Cancer Drug Approvals in 2019 Select Cancer Drug Approvals in 2018 Cancer Drug Pipeline to Change the Pharma Landscape Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019 Global Competitor Market Shares Cancer Therapies Competitor Market Share Scenario Worldwide (in %): 2019 Select Leading Cancer Drugs Worldwide by Sales: 2018

2. FOCUS ON SELECT PLAYERS AbbVie, Inc. (USA) Amgen, Inc. (USA) Astellas Pharma, Inc. (Japan) AstraZeneca Plc. (UK) Bayer AG (Germany) Bristol-Myers Squibb Company (USA) Select Late Stage Compounds in Bristol-Myers Squibb Companys Oncology Pipeline (As of 2019) Celgene Corporation (USA) Eli Lilly and Company (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Glaxosmithkline Plc (UK) Johnson & Johnson Services, Inc. (USA) Merck KGaA (Germany) Novartis AG (Switzerland) Pfizer, Inc. (USA) Takeda Pharmaceutical Company Limited (Japan)

3. MARKET TRENDS & DRIVERS Industry Focuses on New Approaches to Treat Cancer Recent Advancements in Cancer Drug Discovery A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team Lymphoma Therapy Developed by BeiGene Secures US FDA Approval New Linker Technology for Enhancing Stability of ADCs Personalized Medicine Gains Importance Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care North American Companion Diagnostics Market (2019) European Companion Diagnostics Market by Disease Area (2019) Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs Combination Therapy: A Double Whammy Success Patent Expiries of Branded Drugs to Trigger Generic Competition Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer Development of Novel Drug Candidates and Potential Therapies Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies Rise in Patient Assistance Programs (PAPs) Top Financial Concerns for Cancer Patients: Ranked In Order of Influence Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses Growth Drivers and Restraints Demographics & Lifestyles Raise the Risk of Cancer Percentage Breakdown of New Cases for All Cancers by Gender (2019) Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019) Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019) Unmet Needs Leave Scope for Further Research and Development Low Entry Barriers in Cancer Research Encourages Breakthrough Developments Increasing Investments by National Health Authorities NCI Funding for Cancer Research (2002, 2008, 2014 and 2020) Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth Molecular Imaging of Cancer: Critical in Improving Patient Outcomes Innovations, Improvements, and Approvals Propel Growth Select Cancer Drug Approvals (2018 & 2019) Emerging Challenges in Cancer Drug Development Drug Failures Deter Prospects of New Therapies High Prices of Targeted Therapies Act as a Speed Breaker Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016 Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation Limited Tumor Specificity and Toxicity Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance Reduced Smoking Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018 Reimbursement Coverage Remains a Major Challenge Increase in Multidrug Resistance Stringent Regulations Delay Market Approval Challenges Encountered in Clinical Trials Overview of Cancer Therapy Segments Immunotherapy: A Promising Segment Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019 Monoclonal Antibodies for Cancer Treatment Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment Vaccines: A Promising Future Area of Cancer Therapeutics Approved Therapeutic Cancer Vaccines Worldwide CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients Immune Cells for Cancer Treatment UK Researchers New Approach Holds Potential to Boost Immunotherapies Targeted Therapy: An Overview Types of Targeted Therapy Chemotherapy: An Overview Types of Chemotherapy Risks Associated with Chemotherapy Hormone Therapy Drug Classes in Hormone Therapy Cancer Types, Approved and Pipeline Drugs Prostate Cancer Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018 Select General Risk Factors and their Relative Risk Rate in Prostate Cancer Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC) Prostate Cancer Phase IV Completed Clinical Trials with Results Lung Cancer Age-Standardized Lung Cancer Rates for Select Countries Age-Standardized Lung Cancer Rates in Men for Select Countries Age-Standardized Lung Cancer Rates in Women for Select Countries Select FDA-Approved Non-Small Cell Lung Cancer Drugs Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019 Select Phase III Completed Clinical Trials with Results: As of December 30, 2019 Breast Cancer Select FDA Approved Breast Cancer Drugs Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Renal Cancer Select FDA-Approved Renal Cell Carcinoma Drugs Cervical Cancer Colorectal Cancer Select FDA-Approved Colorectal Cancer Drugs Skin Cancer Skin Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Pancreatic Cancer Non-Hodgkins Lymphoma Leukemia Standard Approved Mode of Therapy for AML by Age Group Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Bladder Cancer Endometrial Cancer

4. GLOBAL MARKET PERSPECTIVE Table 1: Cancer Therapies Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 2: Cancer Therapies Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 Table 3: Cancer Therapies Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Chemotherapy (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 5: Chemotherapy (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 6: Chemotherapy (Treatment Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Targeted Therapy (Treatment Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 8: Targeted Therapy (Treatment Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 9: Targeted Therapy (Treatment Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Immunotherapy (Treatment Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 11: Immunotherapy (Treatment Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 12: Immunotherapy (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 13: Hormonal Therapy (Treatment Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2to 2025 Table 14: Hormonal Therapy (Treatment Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 15: Hormonal Therapy (Treatment Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 16: Other Treatment Types (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 17: Other Treatment Types (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 18: Other Treatment Types (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 19: Blood Cancer (Cancer Type) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 Table 20: Blood Cancer (Cancer Type) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 21: Blood Cancer (Cancer Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 Table 22: Breast Cancer (Cancer Type) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 Table 23: Breast Cancer (Cancer Type) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017 Table 24: Breast Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 25: Prostate Cancer (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 26: Prostate Cancer (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 27: Prostate Cancer (Cancer Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 28: Gastrointestinal Cancer (Cancer Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 29: Gastrointestinal Cancer (Cancer Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 30: Gastrointestinal Cancer (Cancer Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 31: Gynecologic Cancer (Cancer Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 32: Gynecologic Cancer (Cancer Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 33: Gynecologic Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 34: Lung Cancer (Cancer Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 Table 35: Lung Cancer (Cancer Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 36: Lung Cancer (Cancer Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 37: Other Cancer Types (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 38: Other Cancer Types (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 39: Other Cancer Types (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Overview Rising Cancer Cases Spur Growth in Anti-Cancer Drugs Market Estimated Number of New Cancer Cases and Deaths in the US (2019) Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018 Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent Personalized Medicine Gathers Momentum for Cancer Treatment in the US A Surging US Prostate Cancer Therapeutics Market Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care CMS Hikes Reimbursement Rate for CAR-T Therapy Market Analytics Table 40: United States Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 41: Cancer Therapies Market in the United States by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 42: United States Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 43: United States Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 44: Cancer Therapies Market in the United States by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 45: United States Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 CANADA Number of New Cancer Cases in Canada: 2019 Market Analytics Table 46: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 47: Canadian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 48: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 49: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 50: Canadian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 51: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 JAPAN Table 52: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 53: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 54: Japanese Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 55: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 56: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 57: Japanese Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 CHINA Cancer Therapies Market: Overview Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products Market Analytics Table 58: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 59: Cancer Therapies Historic Market Analysis in China in US$ Million by Treatment Type: 2009-2017 Table 60: Chinese Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 61: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 62: Cancer Therapies Historic Market Analysis in China in US$ Million by Cancer Type: 2009-2017 Table 63: Chinese Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 EUROPE Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018 Market Analytics Table 64: European Cancer Therapies Market Demand Scenario in US$ Million by Region/Country: 2018-2025 Table 65: Cancer Therapies Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 Table 66: European Cancer Therapies Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 68: Cancer Therapies Market in Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 69: European Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 70: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 71: Cancer Therapies Market in Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 72: European Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 FRANCE Table 73: Cancer Therapies Market in France by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 74: French Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 75: French Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 76: Cancer Therapies Market in France by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 77: French Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 78: French Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 GERMANY Table 79: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 80: German Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 81: German Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 82: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 83: German Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 84: German Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ITALY Table 85: Italian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 86: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Treatment Type: 2009-2017 Table 87: Italian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 88: Italian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 89: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Cancer Type: 2009-2017 Table 90: Italian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED KINGDOM Table 91: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 92: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 93: United Kingdom Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 94: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 95: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 96: United Kingdom Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 SPAIN Table 97: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 98: Spanish Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 99: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 100: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 101: Spanish Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 102: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 RUSSIA Table 103: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 104: Cancer Therapies Market in Russia by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 105: Russian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 106: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 107: Cancer Therapies Market in Russia by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 108: Russian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF EUROPE Table 109: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 110: Cancer Therapies Market in Rest of Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 111: Rest of Europe Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 112: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 113: Cancer Therapies Market in Rest of Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 114: Rest of Europe Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ASIA-PACIFIC An Insight into Asia-Pacific Market for Cancer Therapies Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019 Market Analytics Table 115: Asia-Pacific Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 116: Cancer Therapies Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 Table 117: Asia-Pacific Cancer Therapies Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 118: Cancer Therapies Market in Asia-Pacific by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 119: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 120: Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 121: Cancer Therapies Market in Asia-Pacific by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 122: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 123: Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 AUSTRALIA Table 124: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 125: Australian Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 126: Australian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 127: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 128: Australian Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 129: Australian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 INDIA Table 130: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 131: Indian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 132: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 133: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 134: Indian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 135: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 SOUTH KOREA Table 136: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 137: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 138: Cancer Therapies Market Share Distribution in South Korea by Treatment Type: 2009 VS 2019 VS 2025 Table 139: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 140: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 141: Cancer Therapies Market Share Distribution in South Korea by Cancer Type: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 142: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 143: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 144: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 145: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 146: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 147: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 LATIN AMERICA Table 148: Latin American Cancer Therapies Market Trends by Region/Country in US$ Million: 2018-2025 Table 149: Cancer Therapies Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 Table 150: Latin American Cancer Therapies Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 151: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 152: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Treatment Type: 2009-2017 Table 153: Latin American Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 154: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 155: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Cancer Type: 2009-2017 Table 156: Latin American Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 ARGENTINA Table 157: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 158: Cancer Therapies Market in Argentina in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 159: Argentinean Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 160: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 161: Cancer Therapies Market in Argentina in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 162: Argentinean Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 BRAZIL Table 163: Cancer Therapies Market in Brazil by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 164: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 165: Brazilian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 166: Cancer Therapies Market in Brazil by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 167: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 168: Brazilian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 MEXICO Table 169: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 170: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 171: Mexican Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 172: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 173: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 174: Mexican Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 175: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 176: Cancer Therapies Market in Rest of Latin America by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 177: Rest of Latin America Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 178: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2to 2025 Table 179: Cancer Therapies Market in Rest of Latin America by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 180: Rest of Latin America Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 MIDDLE EAST Table 181: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 182: Cancer Therapies Market in the Middle East by Region/Country in US$ Million: 2009-2017 Table 183: The Middle East Cancer Therapies Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 184: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 185: The Middle East Cancer Therapies Historic Market by Treatment Type in US$ Million: 2009-2017 Table 186: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 187: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 188: The Middle East Cancer Therapies Historic Market by Cancer Type in US$ Million: 2009-2017 Table 189: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 IRAN Table 190: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 191: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 192: Iranian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 193: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 194: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 195: Iranian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 ISRAEL Table 196: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 197: Cancer Therapies Market in Israel in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 198: Israeli Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 199: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 200: Cancer Therapies Market in Israel in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 201: Israeli Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 202: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 203: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Treatment Type: 2009-2017 Table 204: Saudi Arabian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 205: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 206: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Cancer Type: 2009-2017 Table 207: Saudi Arabian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED ARAB EMIRATES Table 208: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 209: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 210: Cancer Therapies Market Share Distribution in United Arab Emirates by Treatment Type: 2009 VS 2019 VS 2025 Table 211: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 212: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 213: Cancer Therapies Market Share Distribution in United Arab Emirates by Cancer Type: 2009 VS 2019 VS 2025 REST OF MIDDLE EAST Table 214: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 215: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 216: Rest of Middle East Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 217: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 218: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 219: Rest of Middle East Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 AFRICA Table 220: African Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 221: Cancer Therapies Market in Africa by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 222: African Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 223: African Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 224: Cancer Therapies Market in Africa by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 225: African Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled : 75 (including Divisions/Subsidiaries - 80) Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more:
Global Cancer Therapies Industry - GlobeNewswire

Recommendation and review posted by Bethany Smith

The global "Gene Therapy Market" research report highlights the need for the up-to-date market data for the business management that will offer development and profitability of the global Gene Therapy market. The research report presents all the essential facts and figures on drifts & growths. It emphasizes on technologies & capacities, materials & markets, and unpredictable structure of the Gene Therapy market. In addition, it also highlights the dominating players in the market joined with their market share. The well-established players in the market are Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical, Advantagene.

Click Here To Access The Report: http://www.99strategy.biz/global-gene-therapy-market-2018-2023-industry-overview.html#request-sample

The global Gene Therapy market report portrays best approaches to assess the global Gene Therapy market. It offers the reliable facts and extensive analysis of the global Gene Therapy market. The report presents a summary of the global Gene Therapy industry, embracing categorizations, applications, and industry chain structure. The study also represents a thorough analysis including significant insights, industry-legalized figures, and facts of the global Gene Therapy market.

Furthermore, the study also assesses the principal aspects of the market that entails revenue, demand, gross value, growth rate, cost, capability, market share, import, gross margin, expenditure, export, manufacture, supply, and so on. A number of methodological tools are used in the global Gene Therapy market analysis. It offers a complete analysis of the market statistics and the estimation of the global Gene Therapy industry players along with their market scope.

Read Detailed Index of full Research Study at:http://www.99strategy.biz/global-gene-therapy-market-2018-2023-industry-overview.html

The research report highlights the assessment of its diverse segments. It also offers analysis of main topographies of the global Gene Therapy market. This profound review portrays the existing market development & drifts, key aspects impelling the market expansion, market projections, drivers, limits, and market structure. The market study also offers analysis of every area of the global Gene Therapy market along with its sub-segments. Additionally, the global Gene Therapy market report covers the major product categories and segments Ex vivo, In vivo along with their sub-segments Cancer Diseases, Monogenic Diseases, Infectious Diseases, Cardiovascular Diseases, Others in detail.

In addition, the study emphasizes the leading market players ruling worldwide. It also provides the user with important details such as sales, contact details, product specifications & pictures, and market share. The assessment also embodies previous and expected data and statistics that make the report an extremely precious reference for advertising individuals, advisors, industry executives, sales & product executives, forecasters, and other personals hunting for crucial industry information in readily handy scripts with outstandingly displayed tables, statistics, and graphs.

There are 15 Chapters to display the Global Gene Therapy market

Chapter 1, Definition, Specifications and Classification of Gene Therapy , Applications of Gene Therapy , Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Gene Therapy , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Gene Therapy Segment Market Analysis (by Type);Chapter 7 and 8, The Gene Therapy Segment Market Analysis (by Application) Major Manufacturers Analysis of Gene Therapy ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Ex vivo, In vivo, Market Trend by Application Cancer Diseases, Monogenic Diseases, Infectious Diseases, Cardiovascular Diseases, Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Gene Therapy ;Chapter 12, Gene Therapy Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Gene Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: http://www.99strategy.biz/global-gene-therapy-market-2018-2023-industry-overview.html#inquiry-for-buying

Reasons for Buying Gene Therapy market

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Read more from the original source:
Global Gene Therapy Market Growth Analysis, Forecasts to 2025:2023: Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon -...

Recommendation and review posted by Bethany Smith

He ate, played and learned like any other kid. But David Vetter's life unfolded in a series of unusual environments: plastic, bubblelike enclosures that protected him from germs. He had severe combined immunodeficiency (SCID), and even a seemingly harmless germ could kill him.

The subject of pop culture scrutiny and medical fascination, David was called "the boy in the bubble" by the US media. SCID is rare and often fatal; it affects about 1 in 58,000 infants.

The disorder is created by genetic mutations that cause patients to produce too few of the immune cells that protect the body from infection. In healthy immune systems, T and B cells known as lymphocytes attack foreign organisms.

READ MORE:*Doctors use HIV in gene therapy to fix 'bubble boy*Eight-month old Kiwiboy facing life in a bubble*'Remarkable' progress in finding cure for HIV

People with SCID lack these critical immune defences.

David, who lived in the US state of Texas, wasn't supposed to grow up in isolation. But while doctors waited for a cure, they decided to keep him in a sterile environment.

Raising a child in plastic isolation was developmentally risky and ethically questionable. But exposing David to the outside world meant death. Doctors thought a cure was just around the corner. Meanwhile, David became a long-term research subject.

GETTY IMAGES

David Vetter, who was born with severe combined immunodeficiency (SCID), plays in the enclosed plastic environment that he was forced to live in to survive. His short life provided insights into how SCID works.

Precocious, bright and sociable, he challenged expectations at every turn. (He did have visual problems that stemmed from being raised entirely in enclosed spaces, and he exhibited symptoms of depression.)

During his long confinement, medical technology progressed. But an experimental bone marrow transplant from his sister was David's death sentence. Undetected Epstein-Barr virus in her marrow triggered lymphoma. He died of the cancer in 1984 at age 12.

Because he was brought up in a sterile environment, his death allowed researchers to confirm a long-standing hypothesis that Epstein-Barr can cause cancer.

David's short life also provided insights into how SCID works. Better bone marrow screening now means more transplants are successful. According to the Immune Deficiency Foundation, 91 per cent of infants who are diagnosed early and given transplants by age 3- months survive.

Today, David's medical records and personal papers are held by the Smithsonian Institution in Washington DC. Perhaps the most touching of the museum's artifacts are his Star Warsaction figures a painful reminder of the child at the centre of a medical drama he could not control.

View original post here:
He was called 'the boy in the bubble.' His short life gave insights into a rare illness - Stuff.co.nz

Recommendation and review posted by Bethany Smith

A new statistical study of the Gene Therapy Industry market was recently published by Healthcare Intelligence Market. Primary and secondary research techniques have been used to provide effective and accurate data to make informative decisions in the businesses.

At the same time, we classify different Sports Drug Testing Device based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What is more, the Gene Therapy Industry industry development trends and marketing channels are analyzed.

Get Sample copy of Report@ https://www.healthcareintelligencemarkets.com/request_sample.php?id=113738

Leading Key Players Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.Advantagene

The global competitive landscape has been elaborated on the basis of analysis of several companies. For an effective analysis, different tools such as Porters five and SWOT analysis have been used. This research report also looks at the latest developments in technologies and business sectors like Gene Therapy Industry. Techniques that will come in handy to explore global opportunities have also been listed in the report.

Gene Therapy Industry Market segmentation, by regions:

North America

Europe

Asia Pacific

Middle East & Africa

Latin America

Others

Special discount on this report@ https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=113738

Market Report includes major TOC points:

Gene Therapy Industry Overview

Global Economic Impact on Industry

Global Market Competition by Manufacturers

Global Production, Revenue (Value) by Region

Global Supply (Production), Consumption, Export, Import by Regions

Global Production, Revenue (Value), Price Trend by Type

Global Market Analysis by Application

Manufacturing Cost Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Gene Therapy Industry Forecast

Objective of Studies:

1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Gene Therapy Industry market.

2. To provide insights about factors affecting the market growth. To analyze the Gene Therapy Industry market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

4. To provide country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Gene Therapy Industry market.

The statistical survey report also offers numerous approaches to discover global opportunities for increasing businesses rapidly. It gives a comprehensive analysis of the global Gene Therapy Industry market which calculates different verticals of businesses such as, production capacity, local consumers, global and local clients, and potential customers.

Enquiry before buying:- for more information ask our expert@ https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=113738

About US

HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare IT industries. Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.

Contact us:

Marvella Lit

Phone no: +1 (888) 616-2766

Address: 90 State Office Center

90 State Street Suite 700, Albany, NY 12207

sales@healthcareintelligencemarkets.com

http://www.healthcareintelligencemarkets.com

Here is the original post:
Exclusive Growth on Gene Therapy Industry Market Forecast by 2020-2026 | Top Key Players: Bluebird Bio,Sangamo,Spark Therapeutics - Briotainment

Recommendation and review posted by Bethany Smith

Analysts predict that Axovant Gene Therapies Ltd (NASDAQ:AXGT) will post earnings per share (EPS) of ($0.63) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Axovant Gene Therapies earnings, with estimates ranging from ($0.66) to ($0.57). Axovant Gene Therapies reported earnings of ($2.16) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 70.8%. The business is expected to report its next quarterly earnings report on Thursday, February 6th.

On average, analysts expect that Axovant Gene Therapies will report full year earnings of ($3.56) per share for the current fiscal year, with EPS estimates ranging from ($5.76) to ($1.84). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.32) per share, with EPS estimates ranging from ($2.84) to ($1.20). Zacks Investment Researchs earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Axovant Gene Therapies.

Axovant Gene Therapies (NASDAQ:AXGT) last posted its earnings results on Friday, November 8th. The company reported ($0.61) earnings per share for the quarter, topping the Thomson Reuters consensus estimate of ($1.15) by $0.54.

Several equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Axovant Gene Therapies from a hold rating to a strong-buy rating and set a $6.00 target price on the stock in a report on Wednesday, November 13th. ValuEngine upgraded shares of Axovant Gene Therapies from a hold rating to a buy rating in a report on Friday. Finally, Chardan Capital raised their price objective on shares of Axovant Gene Therapies from $10.00 to $15.00 and gave the stock a buy rating in a report on Monday, October 28th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $24.72.

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its holdings in shares of Axovant Gene Therapies by 955.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock worth $27,000 after acquiring an additional 3,821 shares during the period. Barclays PLC acquired a new stake in shares of Axovant Gene Therapies during the third quarter worth $65,000. Jane Street Group LLC raised its holdings in shares of Axovant Gene Therapies by 28.8% during the second quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the period. Finally, BlackRock Inc. acquired a new stake in shares of Axovant Gene Therapies during the second quarter worth $1,482,000. Institutional investors and hedge funds own 14.80% of the companys stock.

AXGT opened at $4.95 on Tuesday. The firms fifty day moving average is $5.18 and its two-hundred day moving average is $6.20. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.69. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $19.60.

About Axovant Gene Therapies

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Read More: What is a capital gain?

Get a free copy of the Zacks research report on Axovant Gene Therapies (AXGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
-$0.63 Earnings Per Share Expected for Axovant Gene Therapies Ltd (NASDAQ:AXGT) This Quarter - Riverton Roll

Recommendation and review posted by Bethany Smith

Former Ireland AM presenter Lorraine Keane has told how scheduled sex during her IVF battle took the romance out of her relationship.

The screen and stage star said the scientific approach to making love put a strain on her and musician hubby Peter Devlins marriage.

But the 47-year-old revealed that with the right hormone balance shes bringing sexy back.

Mum-of-two Lorraine opened up on losing clumps of hair, breaking out in adult acne and having a low libido, as the gruelling perimenopause took its grip.

She said her failed IVF attempts were directly linked to her hormone imbalance and she counts herself lucky to have her daughters.

Lorraine told Dublin Live: I kept it to myself for all of the time that we thought it might happen.

It was really difficult to come out and talk about being perimenopausal. But then it made sense to come out and talk about the whole truth.

Maybe I didnt talk about doing IVF during it because I thought, If I do have a baby maybe I wont want to say thats how we conceived.

But then I got such an amazing reaction for opening up about the menopause, it gave me the confidence to speak out and to help other women who may have an opportunity to conceive and maybe their hormones are the reason that theyre not.

Id hate for them to go through three sessions of IVF for all of those reasons, because of the mental and physical harm that it does to you, your wallet as well.

The star admitted the gruelling IVF sessions were tough on her relationship.

She said: It takes the romance out of things, before you even do the business, youre looking at calendars and scheduling in time to have sex, its not very romantic.

Im sure most men are thinking, Id love that but when youre actually in it, the pressure of, Please God make this work it takes away the spontaneity completely.

But thank God myself and Peter always had two healthy babies to go back to.

I feel for people who dont have children, we could count our blessings with the two that we have.

Opening up on her hormonal imbalance, Lorraine said: If you are going to go through menopause then you will go through perimenopause first.

Its a milder version of full-blown menopause Im told.

For example, I havent had a hot flush, or I dont have any problems with my nether regions.

I know during menopause women have terrible pain there, especially during sex, but there is so much help out there, lots of options, whether it be natural, medical, even diet can help.

The symptoms I had were I did get night sweats before I started taking MenoMin and made a visit to endocrinologist Dr Mary Ryan to check my hormone levels.

Clumps of my hair fell out in the shower, it was all hormone related, I had extensions for ages but the worst was the hormonal breakouts, adult acne.

Now I feel balanced, like the 35-year-old me I sleep better (I was waking three to five times a night), my libido has returned, Ive less joint pain, no more hair loss, no hormonal breakouts, I feel brilliant.

Lorraine was approached to front the Cleanmarine brand and despite her initial shock at being approached, shes never looked back.

With perimenopausal symptoms starting when she was 37, she wished she knew her hormones were the main reason she couldnt add to her family. She said: I didnt realise it was something I could fix, maintain and control.

Myself and Peter would have loved to have had more children but we were in one of these situations that was unexplained infertility.

I found out I went into perimenopause very young, normally its 40-plus, I was 37 or 38 going into this.

There I was spending a fortune on IVF, emotionally, physically and mentally suffering through a few phases of it.

Neither one of us were infertile, so it could have been down to hormones and the fact I was in the perimenopause.

I felt low, no energy, very slow, I was annoyed with myself because Ive so much to be grateful for and then Id feel annoyed because I wasnt singing, whistling or being chirpy about life. I discovered taking the right supplements you can have perimenopause and menopause and still be sexy, its just hormones.

Lorraine is urging the public to help support Fashion Relief in aid of Oxfam at Dublins RDS on March 27 and 28.

She said: I travelled to Bangladesh to visit the refugee camp in 2019 and raised 203,000.

To know that theyll have clean safe drinking water and to have a health clinic on site because of Fashion Relief is incredible. Not even half of that will be needed for the camp and it will keep the camp running safely for another year.

The people dont want to be there, but they cant go back home as its unsafe, so at least while there, we know theyll be safe, healthy and educated, weve teachers on site too.

That was down to everyone giving their services and talents for free, the clothes on the day people donate pre-loved designer clothing, it doesnt always have to be designer. Boutiques, wholesalers and designers all donate, its an amazing day out, everything we dont sell goes back into the Oxfam shops.

You can like our main Facebook page here.

Our Dublin Live Sports Page - which brings you all your Dublin sports news - can be found here.

The Dublin Live Twitter account is @DublinLive.

Our Instagram account can be found here.

View original post here:
Lorraine Keane reveals 'scheduled sex' during IVF battle took romance out of relationship - Dublin Live

Recommendation and review posted by Bethany Smith

Protein shakes have become rather essential in this modern era for people of different age groups. It does not just help you to build lean muscles and repair damaged ones, it also gives you the strength to carry out throughout the day without any loss of energy. There are several types of protein shakes in the market. Although all the brands claim to be one of the best in the market, it is not true all the time. Since it is a matter of your own health, it is important that you choose nothing but the best. Thus, TrueFit Lean Protein Shake is a good option for you.

RSP is one of the popular supplement companies that was started by a group of former student-athletes. During the initial days, the company used to concentrate only on bodybuilding products. However, with time, they shifted their focus to more general health supplements. The founders of the company state that they wish the company to become a lifestyle brand that customers can use in their everyday lives.

RSP has come up with several amino acid powder products in the past. However, TrueFit happens to be their flagship product. According to the makers, this protein shake provides users with an ideal balance of veggies, fruits, and high-quality protein, along with 9gm of carbs, dietary fiber, and healthy fats.

Every serving of these health supplements gives you 25gm of protein, 160 calories, 12gm of carbs comprising of 2gm of sugar and 8gm of fiber, and 3gm of fat. Your body will also get approximately 9% of your daily sodium and 20% of your daily cholesterol supply from each scoop. When you talk about the minerals and vitamins in the protein shake, TrueFit comprises of roughly 30% of the daily recommended dose of vitamins and minerals for an adult. This includes vitamins A, B, C, D, E, magnesium, and biotin.

The protein content in TrueFit Lean Protein Shake (see full details at mealreplacementreviewpro.com/rsp-truefit-lean-meal-replacement-reviews) comes from whey isolate and concentrate. The different flavorings of the product also come from natural flavors, cocoa, artificial sweeteners such as sucralose, and stevia. However, the product is free from artificial flavors, colors, and preservatives. Even the content of artificial sweeteners is about less than 0.1gm in each scoop.

The fiber in this product comes from 8.5gm of prebiotic soluble fiber, as well as, from sweet potato powder. It also contains 1gm of a mixture of different types of vegetables and fruits such as berries, broccoli sprouts, carrots, and tomato to name a few. The presence of 7 different digestive enzymes, such as bromelain, protease, lipase, papain, amylase, cellulose, and lactase, as well as, 1 billion probiotic bacteria ensure proper digestive health for you.

From a first timers point of view, it is a good thing that the TrueFit Lean Protein Shake comes with a good list of ingredients that focus on your gut. The pre and probiotics, digestive enzymes, and fiber ensure that your digestive system does not take a beating when you have the protein shake. These ingredients also make sure that all the essential nutrients get absorbed in your system properly, making it a great choice for those of you who suffer from digestive issues.

The high fiber content results in a low amount of net carbs in the shake, which along with low-fat content makes it a great meal replacement. In other words, it is more than a mere protein shake for you. According to the makers, one scoop of the protein shake will give you everything that your body needs in terms of nutrition. It will give you a balanced diet and also ensure that you remain full for quite some time.

However, there are some nutrients that are missing in this product. Nutrients such as choline and vitamin K are missing out in this supplement, which does not make it a nutritionally complete health drink. It even lacks zinc, iron, and potassium and contains a losing percentage of calcium. These are essential nutrients for your health and missing out on these nutrients can be dangerous in the long run.

In short, it can be said that RSP TrueFit Lean Protein Shake is rather good as a high fiber protein nutritious shake that has special attention towards your digestive system. Although it is pretty low in carbs, which is a good thing, it is also quite low in iron, fat, and potassium, which may not be that good for your health.

Continued here:
NHS Mental Health Director Claire Murdoch Warns Game Developers Of Loot Box Risks To Children - The Hear UP

Recommendation and review posted by Bethany Smith